[go: up one dir, main page]

WO2008043644A2 - Utilisation d'extrait de pissenlit pour épaissir les cheveux et stimuler la pousse des cheveux - Google Patents

Utilisation d'extrait de pissenlit pour épaissir les cheveux et stimuler la pousse des cheveux Download PDF

Info

Publication number
WO2008043644A2
WO2008043644A2 PCT/EP2007/059815 EP2007059815W WO2008043644A2 WO 2008043644 A2 WO2008043644 A2 WO 2008043644A2 EP 2007059815 W EP2007059815 W EP 2007059815W WO 2008043644 A2 WO2008043644 A2 WO 2008043644A2
Authority
WO
WIPO (PCT)
Prior art keywords
leontodon
hair
dandelion
taraxacum
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/059815
Other languages
German (de)
English (en)
Other versions
WO2008043644A3 (fr
Inventor
Thomas Welss
Melanie Giesen
Erik Schulze Zur Wiesche
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henkel AG and Co KGaA
Original Assignee
Henkel AG and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel AG and Co KGaA filed Critical Henkel AG and Co KGaA
Publication of WO2008043644A2 publication Critical patent/WO2008043644A2/fr
Publication of WO2008043644A3 publication Critical patent/WO2008043644A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair

Definitions

  • the present invention relates to the use of an agent containing active ingredients which are obtainable from plants of the genus dandelion (Leontodon or Taraxacum) for the treatment of hair.
  • the human skin with its appendages is a very complex organ composed of a variety of different cell types. Every living cell of this organ is able to respond to signals of its internal and external environment. These reactions of the cells are realized by an orderly regulation on gene and protein level, so that the metabolism of skin cells and their appendages is not static but very dynamic. However, the reactions of the skin and / or its appendages to environmental changes should not be considered as reactions of isolated isolated cells. Rather, each cell is integrated into a complex communication network. This network includes e.g. the communication between cells of the epidermis and cells of the dermis. At the communication between the cells of the skin and / or their appendages, signal molecules, e.g. Interleukins, growth factors (e.g., KGF, EGF or FGF), etc. are involved.
  • signal molecules e.g. Interleukins, growth factors (e.g., KGF, EGF or FGF), etc. are involved.
  • Hair follicle cells undergo a genetically determined cycle of growth, regression, and resting phase.
  • the hair follicle is thus the only organ that constantly renews itself and thus, depending on the respective growth phase, has a unique metabolism.
  • the hair follicle's metabolism almost completely stops in the resting phase and is also reinitiated with each new beginning of another cycle.
  • This cycle is controlled by a small, highly specialized cell population in the hair bulb, the dermal papilla cells, which control hair growth through a complex set of molecular signals specific to each phase of the hair cycle (Botchkarev VA et al. (2003) J Investig Dermatol Symp Proc 8: 46-55).
  • the genus dandelion (Leontodon or Taraxacum) probably contains more than 500 different species, some of which are difficult to determine. Alone for the subalpine and alpine level of Austria 70 small species are indicated.
  • the dandelion is already one of the longer known natural herbs. It is known, for example, that dandelion stimulates the digestive organs, as well as the kidneys and bladder, and therefore has a diuretic effect. Furthermore, dandelion is used in folk medicine for blood purification, rheumatic diseases, gout, eczema, liver disease and diuresis.
  • DE 4331252 A1 discloses the use of hair gel for external treatment in the case of hair loss and hair growth, which inter alia comprises cold pressed juice from the cell tissue root meristem of a green weed plant (eg ribwort, dandelion, nettle shrub), mixed with alcohol , contains.
  • a green weed plant eg ribwort, dandelion, nettle shrub
  • DE2255341 describes a hair tonic for the promotion and revival of hair growth which, in addition to other constituents, contains the aqueous extract of dandelion (roots and stems).
  • the agents containing active substances obtained from plants of the genus dandelion are suitable for stimulating the release of growth factors and fortifying the hair by stimulating the proliferation of hair keratinocytes.
  • the present invention therefore relates to the use of an agent containing active compounds which are obtainable from plants of the genus dandelion (Leontodon or Taraxacum) for the treatment of hair, in particular for stimulating hair growth and for thickening and strengthening the hair.
  • an agent containing active compounds which are obtainable from plants of the genus dandelion (Leontodon or Taraxacum) for the treatment of hair, in particular for stimulating hair growth and for thickening and strengthening the hair.
  • Dandelion (Leontodon or Taraxacum) is thereby particularly preferably selected from Leontodon autumnalis (autumn dandelion), Leontodon borii, Leontodon carpetanus, Leontodon cichoraceus, Leontodon crispus (curly dandelion), Leontodon croceus, Leontodon duboisii, Leontodon filii, Leontodon hellecius, Leontodon helveticus (Swiss dandelion), Leontodon hirtus, Leontodon hispidulus, Leontodon hispidus (Steep-haired dandelion or Rough dandelion), Leontodon incanus (Gray dandelion), Leontodon keretinus, Leontodon marracanus, Leontodon mbrocephalus, Leontodon montanus (Mountain dandelion), Leontodon muelleri, Leontodon pyrenaicus, Leontodon
  • Taraxacum officinale of the company Frutarom Switzerland Ltd. is preferred according to the invention.
  • active ingredients obtainable from plants of the genus dandelion (Leontodon or Taraxacum) according to the invention the plant itself, its plant parts, extracts and pressed juices of the dandelion (Leontodon or Taraxacum), in particular from the herb, as well as from these extracts to be recovered active substances understand.
  • Extracts of Taraxacum officinale from the root of the plant.
  • the pressed juices or extracts of herb (the above-ground parts of plants) and / or root, in particular the leaves, fruits, flowers, stems, roots, tubers and / or seeds of the dandelion (Leontodon or Taraxacum) won.
  • aqueous extracts or aqueous-alcoholic extracts or aqueous-organic extracts of the dandelion plant (Leontodon or Taraxacum) or mixtures thereof.
  • the extracts may be prepared with water, as well as polar or nonpolar organic solvents, as well as mixtures thereof in a manner known to those skilled in the art. Extracts which can be obtained by extraction with ethanol or water / ethanol mixtures and press juice are preferred here.
  • the active ingredients of the dandelion plant can also be obtained by extraction with other alcohols, for example with methanol, propanol, isopropanol and / or propylene glycol.
  • extracts in the original extractant and extracts / compressed juice in water or other organic solvents and / or mixtures thereof, in particular ethanol, and also ethanol / water mixtures.
  • extracted or pressed material is used as a solid to which the solvent (in particular as gently as possible) was removed. But it can also be used those extracts / pressed juices, where the solvent was partially withdrawn, so that a thickened extract / pressed juice is used.
  • the extracts and / or compressed juices are used in solid form.
  • the ratio for aqueous-alcoholic extracts is the ratio of alcohol to water between 1: 1 to 1: 2 or 1: 3.
  • KGF keratinocyte growth factor
  • the hair thickness can be strengthened and strengthened. By influencing the hair thickness already in the hair roots, the hair can regrow vigorously and healthy, without
  • the thickening of the hair prevents effects such as "over-care” of the hair.
  • the hair grows from the root to strengthened and with a larger diameter, so that this effect is particularly long-lasting.
  • the hair in its structure, its growth and its metabolism are positively influenced by the inventive application of said agents.
  • the gene expression of the important hair genes was significantly regulated by the use of the agent according to the invention.
  • the active compounds obtainable from plants of the genus dandelion are preferably used in hair treatment compositions, in particular shampoos, hair conditioners, hair gels, hair lotions, hair treatments, hair tonics, hair creams, hair lotions, hair sprays and hair tinctures.
  • the application of these agents is usually topical, wherein the agent simply by spraying into the hair or on the scalp, massage, apply and / or kneading is applied.
  • the agent in the form of hair gel, hair lotions, hair conditioner, hair tonic, hair cream,
  • Hair lotion, hair spray and hair tincture it is usually not necessary but of course possible to rinse the hair or scalp again or treat with other additional means to achieve a positive effect of the applied agent.
  • the agent can be rinsed off after a contact time.
  • This rinsing can be done with pure water or a commercially available shampoo.
  • the active ingredients of the dandelion plant (Leontodon or Taraxacum) can remain in the hair and are not washed out. As a result, a temporally improved penetration of active ingredients is granted to the hair follicle.
  • Active ingredients obtainable from plants of the genus dandelion (Leontodon or Taraxacum), preferably the pressed juices and / or extracts of dandelion (Leontodon or Taraxacum) are preferred in said agents in amounts of 0.001 to 10 wt .-%, based on the entire preparation, included. Amounts of 0.01 to 5 wt .-% are particularly preferred, amounts of 0.01 to 5 wt .-% are particularly preferred, and amounts of 0.01 to 2 wt .-% are very particularly preferred.
  • Haartonics especially as a leave on formulation. These are preferably used at room temperature, the alcoholic content is preferably in the range of about 30% to about 35% and the pH should be about pH 7.
  • the use of liposome-encapsulated drugs that are available from plants of the genus dandelion has proven to be advantageous.
  • the encapsulation of the active compounds obtainable from extracts and / or press juices from the plant of the genus dandelion (Leontodon or Taraxacum), with subsequent encapsulation in liposomes is particularly preferred.
  • Such liposomes can be used in particular in Haartonics.
  • further substances may be encapsulated, which are useful for the application.
  • the agents containing the active ingredients of the plants of the genus dandelion may also be added to other hair treatment agents, such as hair dyes and waving agents become.
  • these agents then optionally contain the known substantive dyes, precursors for oxidation dyes (developer and coupler components) and oxidizing or reducing agents.
  • the agents can thus protect the hair from the stress of dyeing and activate the hair follicles and thus promote hair thickening.
  • the agents used according to the invention can be used, for example, in the form of creams, lotions, solutions, waters, emulsions such as W / O, O / W, PIT emulsions (known as phase inversion emulsions, PIT), microemulsions and multiple emulsions, gels , Sprays, aerosols and foam aerosols are present. These are usually formulated on an aqueous or aqueous-alcoholic basis. As alcoholic component while lower alkanols and polyols such as propylene glycol and glycerol are used. Ethanol and isopropanol are preferred alcohols.
  • Water and alcohol may be present in the aqueous alcoholic base in a weight ratio of 1:10 to 10: 1.
  • Water and aqueous-alcoholic mixtures which contain up to 50% by weight, in particular up to 25% by weight, of alcohol, based on the mixture of alcohol and water, can be preferred bases according to the invention.
  • the pH of these preparations can in principle be between 2 and 11. It is preferably between 2 and 7, with values of 3 to 5 being particularly preferred.
  • acids are used as acids. Acid acids are understood to mean those acids which are absorbed as part of normal food intake and have positive effects on the human organism.
  • Exotic acids are, for example, acetic acid, lactic acid, tartaric acid, citric acid, malic acid, ascorbic acid and gluconic acid.
  • citric acid and lactic acid is particularly preferred.
  • Preferred bases are ammonia, alkali hydroxides, triethanolamine and N, N, N ', N'-tetrakis (2-hydroxypropyl) ethylenediamine.
  • the funds can be made up as a single-chamber system or as a two-chamber system.
  • the agents used in the invention may in principle contain all other known to those skilled in such cosmetic means components.
  • the agents used according to the invention may preferably additionally comprise protein hydrolysates.
  • they are cationized protein hydrolysates, wherein the underlying protein hydrolyzate is derived from the animal, for example from collagen, milk or keratin, from the plant, for example from wheat, corn, rice, potatoes, soy or almonds, from marine life forms, for example from fish collagen or algae, or biotechnologically derived protein hydrolysates.
  • the protein hydrolyzates on which the cationic derivatives are based can be obtained from the corresponding proteins by chemical, in particular alkaline or acid hydrolysis, by enzymatic hydrolysis and / or a combination of both types of hydrolysis.
  • the hydrolysis of proteins usually results in a protein hydrolyzate having a molecular weight distribution of about 100 daltons up to several thousand daltons. Preference is given to those cationic protein hydrolyzates whose underlying protein content has a molecular weight of 100 to 25,000 daltons, preferably 250 to 5000 daltons.
  • cationic protein hydrolyzates are to be understood as meaning quaternized amino acids and mixtures thereof.
  • Quaternization of the protein hydrolyzates or amino acids is often carried out using quaternary ammonium salts such as N, N-dimethyl-N- (n-alkyl) -N- (2-hydroxy-3-chloro-n-propyl) ammonium halides.
  • quaternary ammonium salts such as N, N-dimethyl-N- (n-alkyl) -N- (2-hydroxy-3-chloro-n-propyl) ammonium halides.
  • the cationic protein hydrolysates may also be further derivatized.
  • cationic protein hydrolysates and derivatives those listed under the INCI names in the "International Cosmetic Ingredient Dictionary and Handbook", (seventh edition 1997, The Cosmetic, Toiletry, and Fragrance Association 1101 17 th Street, NW, Suite 300, Washington, DC 20036-4702) and cited: Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimopnium Hydroxypropyl Hydrolyzed Casein, Cocodimonium Hydroxypropyl Hydrolyzed Collagen, Cocodimonium Hydroxypropyl Hydrolyzed Hair Keratin, Cocodimonium Hydroxypropyl Hydrolyzed Keratin, Cocodimonium Hydroxypropyl Hydrolyzed Rice Protein, Cocodimonium Hydroxypropyl Hydrolyzed SiC, Cocodimonium Hydroxypropyl Hydrolyzed Soy Protein, Cocodimonium Hydroxypropyl Hydrolyzed Wheat Protein, Cocodimonium Hydroxypropyl SiCl Amino Acids, Hydroxy
  • film-forming substances can additionally be incorporated into the formulations, which are absorbed by the hair and thus thicken directly and perceptibly.
  • Suitable preferred film formers are known to those skilled in the art and are selected, for example, from polymers, e.g. Polyvinyl alcohol or polyvinylpyrrolidone and copolymers thereof.
  • such an agent used according to the invention contains a hair growth stimulating agent.
  • hair growth stimulating agents are those compounds which are selected from 5- ⁇ -
  • Minoxidil (6-piperidino-2,4-pyrimidinediamine-3-oxide) and Aminexil
  • Particularly suitable 5- ⁇ -reductase inhibitors are functional C 2 -C 12 -carboxylic acids and their physiologically tolerable metal salts, in particular 10-hydroxydecanoic acid,
  • Plant extracts fragrances, flavonoids, isoflavonoids, 6,7-disubstituted
  • derivatives are meant in particular their salts, esters and amides.
  • the hair growth-stimulating effect of the active ingredients can be improved by their use in agents containing active ingredients which are obtainable from plants of the genus dandelion (Leontodon or Taraxacum).
  • agents containing active ingredients which are obtainable from plants of the genus dandelion (Leontodon or Taraxacum).
  • the hair growth stimulating agent is also selected in this combination from minoxidil and finasteride.
  • compositions according to the invention are, for example, nonionic surfactants such as, for example, alkylphenol polyglycol ethers, fatty acid polyglycol esters, fatty acid amide polyglycol ethers, fatty amine polyglycol ethers, alkoxylated triglycerides, in particular ethoxylated castor oil, alk (en) yloligoglucosides, fatty acid polyglycol ethers.
  • nonionic surfactants such as, for example, alkylphenol polyglycol ethers, fatty acid polyglycol esters, fatty acid amide polyglycol ethers, fatty amine polyglycol ethers, alkoxylated triglycerides, in particular ethoxylated castor oil, alk (en) yloligoglucosides, fatty acid polyglycol ethers.
  • nonionic surfactants such as, for example, alkylphenol polyglycol
  • nonionic surfactants contain polyglycol ether chains, they may have a conventional or narrow homolog distribution.
  • anionic surfactants in particular alkyl sulfates, alkyl polyglycol ether sulfates and ether carboxylic acids having 10 to 18 carbon atoms in the alkyl group and up to 12 glycol ether groups in the molecule, soaps and sulfosuccinic mono- and
  • zwitterionic surfactants in particular the so-called betaines such as N-alkyl-N , N-dimethylammonium glycinates, for example, the cocoalkyl dimethylammonium glycinate, N-acylaminopropyl N, N-dimethylammoniumglycinate, for example Kokosacylaminopropyl- dimethylammoniumglycinat, and 2-alkyl-3-carboxylmethyl-3-hydroxyethyl imidazoline with in each case 8 to 18 C atoms in the alkyl or acyl group and the cocoacylaminoethylhydroxyethylcarboxymethylglycinate, ampholytic surfactants such as,
  • methylcellulose, hydroxyalkylcellulose and carboxymethylcellulose starch fractions and derivatives such as amylose, amylopectin and dextrins, clays such.
  • bentonite or fully synthetic hydrocolloids such.
  • polyvinyl alcohol structurants such as maleic acid and lactic acid
  • hair conditioning compounds such as phospholipids, such as soybean lecithin, egg lecithin and cephalins, and silicone oils, Perfume oils, dimethylisosorbide and cyclodextrins,
  • Solvents and mediators such as ethanol, isopropanol, ethylene glycol, propylene glycol, glycerol and
  • 12 to 36 C atoms in particular 12 to 24 C atoms, such as, for example, di-n-octyl ether, di-n-decyl ether, di-n-nonyl ether, di-n-undecyl ether and di-n-dodecyl ether, n-hexyl -n-octyl ether, n-
  • Fatty alcohols in particular linear and / or saturated fatty alcohols having 6 to 30 C atoms, and
  • Fatty acid fiber structure-improving agents in particular mono-, di- and oligosaccharides, such as glucose, galactose, fructose, fructose and lactose, conditioning agents such as paraffin oils, vegetable oils, eg. Sunflower oil, orange oil,
  • Lecithin and cephaline quaternized amines such as methyl-1-alkylamidoethyl-2-alkylimidazolinium methosulfate,
  • Anti-dandruff agents such as Piroctone Olamine, Zinc Omadine and Climbazole,
  • Light stabilizers in particular derivatized benzophenones, cinnamic acid derivatives and triazines, other substances for adjusting the pH, such as ⁇ - and ß-
  • Active ingredients such as allantoin and bisabolol,
  • Bodying agents such as sugar esters, polyol esters or polyol alkyl ethers,
  • Swelling and penetration substances such as glycerol, propylene glycol monoethyl ether, carbonates,
  • Opacifiers such as latex, styrene / PVP and styrene / acrylamide copolymers
  • Pearlescing agents such as ethylene glycol mono- and distearate and PEG-3-distearate,
  • Reducing agents such as B. thioglycolic acid and its derivatives, thiolactic acid, cysteamine,
  • Thiomalic acid and ⁇ -mercaptoethanesulfonic acid Thiomalic acid and ⁇ -mercaptoethanesulfonic acid, Propellants such as propane-butane mixtures, N 2 O, dimethyl ether, CO 2 and air, antioxidants.
  • Preferred fatty alcohols are saturated, mono- or polyunsaturated, branched or unbranched fatty alcohols with C 6 -C 30, preferably C 10 -C 22 and very particularly preferably C 12 -C 22, carbon atoms.
  • the fatty alcohols are derived from preferably natural fatty acids, which can usually be based on recovery from the esters of fatty acids by reduction.
  • those fatty alcohol cuts which are produced by reduction of naturally occurring triglycerides such as beef tallow, palm oil, peanut oil, rapeseed oil, cottonseed oil, soybean oil, sunflower oil and linseed oil or fatty acid esters formed from their transesterification products with corresponding alcohols, and thus represent a mixture of different fatty alcohols.
  • Such substances are known, for example, under the names Stenol®, e.g. Stenol® 1618 or Lanette®, e.g. Lanette® O or Lorol®, e.g.
  • wool wax alcohols such as are commercially available under the names Corona®, White Swan®, Coronet® or Fluilan®, can also be used.
  • the fatty alcohols are used in amounts of from 0.1 to 30% by weight, based on the total preparation, preferably in amounts of from 0.1 to 20% by weight.
  • the fatty acids used may preferably be linear and / or branched, saturated and / or unsaturated fatty acids having 6 to 30 carbon atoms. Preference is given to fatty acids having 10 to 22 carbon atoms. These include, for example, the isostearic acids, such as the commercial products Emersol® 871 and Emersol® 875, and isopalmic acids, such as the commercial product Edenor® IP 95, as well as all other fatty acids sold under the trade names Edenor® (Cognis).
  • fatty acids are caproic, caprylic, 2-ethylhexanoic, capric, lauric, isotridecanoic, myristic, palmitic, palmitoleic, stearic, isostearic, oleic, elaidic, petroselic, linoleic, linolenic and erucic acid and their technical mixtures, for example, in the pressure splitting of natural fats and oils, in the oxidation of aldehydes from the Roelen oxo synthesis or the dimerization of unsatisfactory incurred fatty acids.
  • Particularly preferred are usually the fatty acid cuts, which consist of
  • coconut oil or palm oil are available; In particular, the use of is usually preferred
  • the amount used is 0.1 - 15 wt.%, Based on the total mean.
  • the amount is preferably 0.1-10% by weight, with amounts of 0.1-5% by weight being particularly advantageous.
  • waxes solid paraffins or isoparaffins, montan wax, carnauba waxes, beeswaxes, candelilla waxes, ozokerites, ceresin, spermaceti, sunflower wax, fruit waxes such as apple wax or citrus wax, microwaxes of PE or PP may preferably be used according to the invention.
  • Such waxes are available, for example, from Kahl & Co., Trittau.
  • the amount used is 0.1-50 wt.% Based on the total agent, preferably 0.1 to 20 wt.% And particularly preferably 0.1 to 15 wt.% Based on the total agent.
  • the natural and synthetic cosmetic oil bodies which can advantageously be used according to the invention include, for example: vegetable oils.
  • vegetable oils examples include sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil, orange oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil.
  • triglyceride oils such as the liquid portions of beef tallow as well as synthetic triglyceride oils.
  • Ester oils are the esters of C6-C30 fatty acids with C2-C30 fatty alcohols.
  • the monoesters of the fatty acids with alcohols having 2 to 24 carbon atoms are preferred.
  • Examples of fatty acid components used in the esters are caproic, caprylic, 2-ethylhexanoic, capric, lauric, isotridecanoic, myristic, palmitic, palmitoleic, stearic, isostearic, oleic, elaidic, petroselic, linoleic, linolenic Behenic acid and erucic acid and their technical mixtures which are obtained, for example, in the pressure splitting of natural fats and oils, in the oxidation of aldehydes from Roelen's oxo synthesis or the dimerization of unsaturated fatty acids.
  • fatty alcohol moieties in the ester oils are Isopropyl alcohol, caproic alcohol, capryl alcohol, 2-ethylhexyl alcohol, capric alcohol, lauryl alcohol, isotridecyl alcohol, myristyl alcohol, cetyl alcohol, palmoleyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, elaidyl alcohol, petroselinyl alcohol, linolyl alcohol, linolenyl alcohol, elaeostearyl alcohol, arachyl alcohol, gadoleyl alcohol, behenyl alcohol, erucyl alcohol and brassiyl alcohol.
  • dyl alcohol and their technical mixtures which are obtained, for example, in the high-pressure hydrogenation of technical methyl esters based on fats and oils or aldehydes from Roelen's oxosynthesis and as a monomer fraction in the dimerization of unsaturated fatty alcohols.
  • isopropyl myristate (Rilanit® IPM), isononanoate C16-18-alkyl ester (Cetiol® SN), 2-ethylhexyl palmitate (Cegesoft® 24), stearic acid 2-ethylhexyl ester (Cetiol® 868), cetyl oleate, glycerol tricaprylate, coconut fatty alcohol caprinate caprylate (Cetiol® LC), n-butyl stearate, oleyl erucate (Cetiol® J 600), isopropyl palmitate (Rilanit® IPP), oleyl oleate (Cetiol®), lauric acid hexyl ester (Cetiol® A), di-n-butyl adipate (Cetiol® B) , Myristyl myristate (C
  • Dicarboxylic acid esters such as di-n-butyl adipate, di- (2-ethylhexyl) adipate, di- (2-ethylhexyl) succinate and di-isotridecyl acelate
  • diol esters such as ethylene glycol dioleate, ethylene glycol diisotridecanoate, propylene glycol di (2) ethylhexanoate), propylene glycol diisostearate, propylene glycol di-pelargonat, butanediol di-isostearate, Neopentylglykoldicaprylat, symmetrical, asymmetric or cyclic esters of carbonic acid with fatty alcohols, for example described in DE-OS 197 56 454, glycerol carbonate or dicaprylyl carbonate (Cetiol ® CC),
  • Fatty acid partial glycerides ie monoglycerides, diglycerides and their technical mixtures. With the use of technical products production reasons may still contain small amounts of triglycerides.
  • the amount used of the natural and synthetic cosmetic oil bodies in the compositions used according to the invention is usually 0.1 to 30% by weight, based on the total composition, preferably 0.1 to 20% by weight, and in particular 0.1 to 15% by weight. -%.
  • the agents used in the invention may also contain surfactants. These may be anionic, ampholytic, zwitterionic or nonionic surfactants as well as cationic surfactants.
  • a combination of anionic and nonionic surfactants or a combination of anionic and amphoteric surfactants used in a preferred embodiment of the present invention.
  • a combination of anionic and nonionic surfactants or a combination of anionic and amphoteric surfactants used in a preferred embodiment of the present invention.
  • the skilled person can also largely or completely dispense with the use of surfactants.
  • Suitable anionic surfactants in the agents used according to the invention are all anionic surfactants suitable for use on the human body. These are characterized by a water-solubilizing, anionic group such as. As a carboxylate, sulfate, sulfonate or phosphate group and a lipophilic alkyl group having about 8 to 30 carbon atoms. In addition, glycol or polyglycol ether groups, ester, ether and amide groups and hydroxyl groups may be present in the molecule.
  • anionic surfactants are, in each case in the form of the sodium, potassium and ammonium as well as the mono-, di- and trialkanolammonium salts having 2 to 4 C atoms in the alkanol group, linear and branched fatty acids having 8 to 30 ° C Atoms (soaps),
  • Sulfosuccinic acid mono-alkyl polyoxyethyl esters having 8 to 24 carbon atoms in the alkyl group and 1 to 6 oxyethyl groups, linear alkanesulfonates having 8 to 24 carbon atoms, linear alpha-olefin sulfonates having 8 to 24 carbon atoms,
  • Alpha-sulfofatty acid methyl esters of fatty acids having 8 to 30 carbon atoms, - alkyl sulfates and alkyl polyglycol ether sulfates of the formula RO (CH 2 -CH 2 O) x-OSO 3 H, in which R is a preferably linear alkyl group having 8 to 30 carbon atoms and x 0 or 1 to 12,
  • esters of tartaric acid and citric acid with alcohols which are adducts of about 2-15 molecules of ethylene oxide and / or propylene oxide with fatty alcohols containing 8 to 22 carbon atoms, alkyl and / or alkenyl ether phosphates, sulfated fatty acid alkylene glycol esters, monoglyceride sulfates and monoglyceride ether sulfates, amide ether carboxylic acids as described in US Pat EP 0 690 044, condensation products of C8 - C30 fatty alcohols with protein hydrolysates and / or amino acids and derivatives thereof which are known to the person skilled in the art as protein fatty acid condensates, for example the Lamepon® types, Gluadin® types, Hostapon® KCG or the Amisoft® types.
  • Preferred anionic surfactants are alkyl sulfates, alkyl polyglycol ether sulfates and ether carboxylic acids having from 10 to 18 carbon atoms in the alkyl group and up to 12 glycol ether groups in the molecule, sulfosuccinic acid mono- and dialkyl esters having from 8 to 18 carbon atoms in the alkyl group and sulfosuccinic acid monoalkylpolyoxyethyl esters with 8 to 18 carbon atoms in the alkyl group and 1 to 6 oxyethyl groups, Monoglycerdisulfate, alkyl and Alkenyletherphosphate and protein fatty acid condensates.
  • Nonionic surfactants contain as hydrophilic group z.
  • Such compounds are, for example
  • Polyol fatty acid esters such as the commercial product Hydagen® HSP (Cognis) or Sovermol types (Cognis), alkoxylated triglycerides, alkoxylated fatty acid alkyl esters,
  • the preferred nonionic surfactants are the alkylene oxide addition products of saturated linear fatty alcohols and fatty acids having in each case 2 to 30 moles of ethylene oxide per mole of fatty alcohol or fatty acid. Preparations having excellent properties are also obtained if they contain fatty acid esters of ethoxylated glycerol as nonionic surfactants.
  • Particularly preferred nonionic surfactants are alkyl polyglycosides of the general formula R 1 O- (Z) x . These connections are identified by the following parameters.
  • the alkyl radical R 1 contains 6 to 22 carbon atoms and may be both linear and branched. Preference is given to primary linear and methyl-branched in the 2-position aliphatic radicals.
  • Such alkyl radicals are, for example, 1-octyl, 1-decyl, 1-lauryl, 1-myristyl, 1-cetyl and 1-stearyl. Particularly preferred are 1-octyl, 1-decyl, 1-lauryl, 1-myristyl.
  • oxo-alcohols When so-called "oxo-alcohols" are used as starting materials, compounds with an odd number of carbon atoms in the alkyl chain predominate.
  • the alkyl polyglycosides which can be used according to the invention can contain, for example, only one particular alkyl radical R 1 .
  • these compounds are prepared starting from natural fats and oils or mineral oils.
  • the alkyl radicals R are mixtures corresponding to the starting compounds or corresponding to the particular work-up of these compounds.
  • R 1 consists essentially of C 8 and C 10 alkyl groups, essentially of C 12 and C 14 alkyl groups, essentially of C 8 to C 16 alkyl groups or essentially of C 12 - to C 16 alkyl groups.
  • sugar building block Z it is possible to use any desired mono- or oligosaccharides. Usually, sugars with 5 or 6 carbon atoms and the corresponding oligosaccharides are used.
  • Such sugars are, for example, glucose, fructose, galactose, arabinose, ribose, xylose, lyxose, allose, altrose, mannose, gulose, idose, talose and sucrose.
  • Preferred sugar building blocks are glucose, fructose, galactose, arabinose and sucrose; Glucose is particularly preferred.
  • alkyl polyglycosides which can be used according to the invention contain on average from 1.1 to 5 sugar units. Alkyl polyglycosides having x values of 1.1 to 1.6 are preferred. Very particular preference is given to alkyl glycosides in which x is 1: 1 to 1, 4.
  • the alkyl glycosides can also serve to improve the fixation of fragrance components on the hair.
  • this substance class as a further constituent of the preparations according to the invention in the event that an effect of the perfume oil on the hair which exceeds the duration of the hair treatment is desired.
  • alkoxylated homologs of said alkyl polyglycosides can also be used according to the invention. These homologs may contain on average up to 10 ethylene oxide and / or propylene oxide units per alkyl glycoside unit.
  • zwitterionic surfactants can be used, in particular as cosurfactants.
  • Zwitterionic surfactants are surface-active compounds which carry at least one quaternary ammonium group and at least one -COO () or -SO 3 () group in the molecule.
  • Particularly suitable zwitterionic surfactants are the so-called betaines, such as the N-alkyl-N, N-dimethylammonium glycinates, for example the cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammoniumglycinate, for example the cocoacylaminopropyldimetic acid thylammoniumglycinat, and 2-alkyl-3-carboxylmethyl-3-hydroxyethyl imidazoline having in each case 8 to 18 carbon atoms in the alkyl or acyl group and the Kokosacylaminoethylhydroxyethylcarboxymethylgly- cinate.
  • a preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name Cocamidopropyl Betaine.
  • ampholytic surfactants are surface-active compounds which, in addition to a C 8 alkyl- -C 8 -alkyl or acyl group, contain at least one free amino group and at least one -COOH or - contain SO 3 H group and are capable of forming inner salts
  • suitable ampholytic surfactants are N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 18 C - Atoms in the alkyl group.
  • Particularly preferred ampholytic surfactants are N-cocoalkyl aminopropionate the, cocoacylamino
  • the cationic surfactants used are, in particular, those of the quaternary ammonium compound type, the esterquats and the amidoamines.
  • Preferred quaternary ammonium compounds are ammonium halides, in particular chlorides and bromides, such as alkyltrimethylammonium chlorides, dialkyldimethylammonium chlorides and trialkyl methylammonium chlorides, eg. Cetyltrimethylammonium chloride, stearyltrimethylammonium chloride, distearyldimethylammonium chloride, lauryldimethylammonium chloride, lauryldimethylbenzylammonium chloride and tricetylmethylammonium chloride, as well as the imidazolium compounds known under the INCI names Quaternium-27 and Quaternium-83.
  • the long alkyl chains of the above-mentioned surfactants preferably have 10 to 18 carbon atoms.
  • Esterquats are known substances which contain both at least one ester function and at least one quaternary ammonium group as a structural element.
  • Preferred ester quats are quaternized ester salts of fatty acids with triethanolamine, quaternized ester salts of fatty acids with diethanolalkylamines and quaternized ester salts of fatty acids with 1,2-dihydroxypropyldialkylamines.
  • Such products are marketed under the trade names Stepantex® ®, ® and Dehyquart® Armocare® ®.
  • the alkylamidoamines are usually prepared by amidation of natural or synthetic fatty acids and fatty acid cuts with dialkylaminoamines.
  • An inventively particularly suitable compound from this group of substances under the name Tegoamid ® S 18 commercial stearamidopropyl dimethylamine is.
  • the compounds used as surfactant with alkyl groups may each be uniform substances. However, it is generally preferred to use native vegetable or animal raw materials in the production of these substances, so that substance mixtures having different alkyl chain lengths depending on the respective raw material are obtained.
  • both products with a "normal” homolog distribution and those with a narrow homolog distribution can be used.
  • "normal” homolog distribution are meant mixtures of homologs which obtained in the reaction of fatty alcohol and alkylene oxide using alkali metals, alkali metal hydroxides or alkali metal alkoxides as catalysts. Narrowed homolog distributions, on the other hand, are obtained when, for example, hydrotalcites, alkaline earth metal salts of ether carboxylic acids, alkaline earth metal oxides, hydroxides or alcoholates are used as catalysts. The use of products with narrow homolog distribution may be preferred.
  • vitamins, pro-vitamins and vitamin precursors are preferred, which are usually assigned to groups A, B, C, E, F and H.
  • vitamin A includes retinol (vitamin A1) and 3,4-didehydroretinol (vitamin A2).
  • the ß-carotene is the provitamin of retinol.
  • vitamin A component according to the invention for example, vitamin A acid and its esters, vitamin A aldehyde and vitamin A alcohol and its esters such as the palmitate and the acetate into consideration.
  • the preparations used according to the invention preferably contain the vitamin A component in amounts of 0.05-1% by weight, based on the total preparation.
  • the vitamin B group or the vitamin B complex include u. a. Vitamin B1 (thiamine)
  • Vitamin B3 the compounds nicotinic acid and nicotinamide (niacinamide) are often performed.
  • Preferred according to the invention is the nicotinic acid amide, which is preferably contained in the agents according to the invention in amounts of from 0.05 to 1% by weight, based on the total agent.
  • Vitamin B5 pantothenic acid, panthenol and pantolactone.
  • Panthenol and / or pantolactone are preferably used in the context of this group.
  • Derivatives of panthenol which can be used according to the invention are, in particular, the esters and ethers of panthenol and also cationically derivatized panthenols. Individual representatives are, for example, the panthenol triacetate, the panthenol monoethyl ether and its monoacetate and also the cationic panthenol derivatives disclosed in WO 92/13829.
  • the said compounds of the vitamin B5 type are contained in the agents used according to the invention preferably in amounts of 0.05-10% by weight, based on the total agent. Amounts of 0.1-5 wt .-% are particularly preferred.
  • Vitamin B6 pyridoxine and pyridoxamine and pyridoxal.
  • Vitamin C ascorbic acid. Vitamin C is used in the compositions according to the invention preferably in amounts of 0.1 to 3 wt .-%, based on the total agent.
  • Use in the form of palmitic acid ester, glucosides or phosphates may be preferred.
  • the use in combination with tocopherols may also be preferred.
  • Vitamin E tocopherols, especially ⁇ -tocopherol.
  • Tocopherol and its derivatives which include in particular the esters such as the acetate, the nicotinate, the phosphate and the succinate, are preferably present in the agents used according to the invention in amounts of 0.05-1% by weight, based on the total agent ,
  • Vitamin F is usually understood as meaning essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid.
  • Vitamin H is the compound (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4-d] imidazole-4-valeric acid, for which, however, the trivial name biotin has meanwhile prevailed.
  • Biotin is contained in the agents used according to the invention preferably in amounts of 0.0001 to 1, 0 wt .-%, in particular in amounts of 0.001 to 0.01 wt .-%.
  • the preparations used according to the invention preferably contain vitamins, provitamins and vitamin precursors from groups A, B, E and H. Of course, several vitamins and vitamin precursors may also be present at the same time.
  • Panthenol, pantolactone, pyridoxine and its derivatives as well as nicotinic acid amide and biotin are particularly preferred.
  • the amount of vitamins and vitamin precursors used in the compositions according to the invention is usually 0.0001-10% by weight, based on the total agent, preferably 0.0001-5% by weight, and in particular 0.0001-3% by weight. %.
  • One or more of these plant extracts may be used in the agents used, the active compounds which are obtainable from plants of the genus dandelion (Leontodon or Taraxacum).
  • the plant extracts can be used according to the invention both in pure and in diluted form. If they are used in diluted form, they usually contain about 2 to 80 wt .-% of active substance and as a solvent used in their extraction agent or extractant mixture.
  • an object of the present invention is the use of an agent containing active ingredients which are obtainable from plants of the genus dandelion (Leontodon or Taraxacum), which agent may contain additional ingredients selected from protein hydrolysates, film-forming substances, other hair growth stimulating agents, nonionic surfactants , anionic surfactants, zwitterionic surfactants, ampholytic surfactants, nonionic polymers, thickeners, perfume oils, dyes, light stabilizers, antioxidants, anti-dandruff agents, blowing agents and / or reducing agents.
  • additional ingredients selected from protein hydrolysates, film-forming substances, other hair growth stimulating agents, nonionic surfactants , anionic surfactants, zwitterionic surfactants, ampholytic surfactants, nonionic polymers, thickeners, perfume oils, dyes, light stabilizers, antioxidants, anti-dandruff agents, blowing agents and / or reducing agents.
  • Another object of the present invention is the use, in particular the cosmetic use for vitalization of hair, stimulation of energy metabolism in hair follicles, activation of hair follicles, promotion or enhancement of hair growth, hair thickening, treatment of hair loss and hair conditioning.
  • an agent containing active compounds which are obtainable from plants of the genus dandelion (Leontodon or Taraxacum) for the treatment of hair.
  • the active substances are obtained from compressed juices and / or extracts of the plants of the genus dandelion (Leontodon or Taraxacum).
  • a further subject matter of the present invention is a process, in particular a cosmetic process, for revitalizing hair, stimulating energy metabolism in hair follicles, activating hair follicles, promoting or enhancing hair growth, hair thickening, treatment of hair loss and for hair conditioning.
  • active ingredients obtainable from plants of the genus dandelion (Leontodon or Taraxacum), applied to the hair or the hairy skin
  • PROPYLENE GLYCOL PEG-55 PROPYLENE GLYCOL OLEATE
  • Cutina CP V (formerly) Cutina CP PF (formerly) Cognis Germany GmbH Cetyl palmitate (vegetable base) CETYL PALMITATE
  • Neutrol TE BASF Tetrakis (2-hydroxypropyl) ethylenediamine * N, N, N ', N', - Edetol TETRAHYDROXYPROPYL ETHYLENEDIAMINE
  • Example 7 Determination of cell vitality of cultured fibroblasts after treatment with dandelion extract
  • the determination of the vitality of cultured cells provides information about the status of the cells. With this analysis, both cell-damaging substance concentrations can be defined, as well as cell-activating drug effects can be determined.
  • the vitality of cultured cells is determined by redox dyes. These dyes penetrate into the cell and are reduced by electron uptake on the outer mitochondrial membrane. This reduction requires a dye change, which is determined photometrically below.
  • the untreated control is set equal to 100% and the readings of the substance-treated samples are referenced thereto. At a relative vitality of less than 80% one speaks of cell-damaging, with greater / equal to 120% of cell-activating substance effects.
  • Example 8 Determination of the proliferation of fibroblasts after treatment with dandelion extract
  • the determination of the proliferation of cultured cells provides information about the status of the cell division of the treated cells. With this analysis, both cell division stimulating and inhibiting substances can be defined. An outstanding feature during cell division is the doubling of the DNA. During the new synthesis, nucleotides are incorporated into the newly formed DNA strand. The proliferation can be measured by offering a non-natural nucleotide derivative (Bromo deoxy uridine, BrdU) to the cells for re-synthesis, which can subsequently be detected with specific antibodies. The amount of newly synthesized DNA can now be fluorometrically guantified and provides proportional information about the degree of cell division processes.
  • a non-natural nucleotide derivative Bromo deoxy uridine, BrdU
  • the untreated control is set equal to 100% and the measurements of the substance-treated samples are referenced thereto.
  • the measurements of the substance-treated samples are referenced thereto.
  • a relative proliferation of less than 80% one speaks of inhibitory, with greater / equal to 120% of stimulating substance effects.
  • Test concentration ( ⁇ g / ml) 0 62.5 125 250 500
  • HGF Hepatocyte Growth Factor
  • KGF Keratinocyte Growth Factor
  • the differential gene expression of the target genes was determined by means of quantitative reverse transcription polymerase chain reaction (QRT-PCR) -PCR. After culturing the dermal papilla cells, they were incubated with dandelion extract at concentrations of 0.1 and 0.01% for 6 to 72 hours.
  • QRT-PCR quantitative reverse transcription polymerase chain reaction
  • the RNA is first isolated from the dermal papilla cells using the RNeasy Mini Kit from Qiagen and transcribed into cDNA by means of reverse transcription.
  • the subsequent PCR reaction which is carried out with the aid of gene-specific primers for the respective hair-relevant genes and which serves to amplify the gene sections sought, the formation of the PCR products is detected online via a fluorescence signal.
  • the fluorescence signal is proportional to the amount of the PCR product formed. The stronger the expression of a particular gene, the greater the amount of PCR product produced and the higher the fluorescence signal.
  • the untreated control is set equal to 1 and the expression of the genes to be determined referred to (x-fold expression).
  • values which are greater than or equal to twice the expression or less than or equal to the O. ⁇ fachen expression of the untreated control are classified as significantly differentially expressed.
  • Treatment with dandelion extract results in significant induction of KGF gene expression. Based on this expression profile, induction of keratinocyte proliferation and thus hair thickening can be inferred. The tendency for reduced expression of IGF BP3, however, indicates a better stimulation of hair growth.
  • Hepatocyte Growth Factor HGF
  • Keratinocyte Growth Factor KGF
  • HGF Hepatocyte Growth Factor
  • KGF Keratinocyte Growth Factor
  • the organotypic hair follicle model was incubated with dandelion extract for 72 h and the concentration of growth factors in the medium was quantified in the manner described.
  • Table 4 Increase in KGF and HGF release in [%] after treatment of the organotypic hair follicle model compared to untreated controls with dandelion extract 0.1%
  • the treatment with dandelion extract (0.1%) after treatment of the hair follicle model leads to a significant increase of HGF protein release by 142% compared to the untreated control.
  • the growth factor KGF was not affected.
  • the difference to the results of the differential gene expression shown in example 3 lies in the fact that here an end point of the accumulated growth factors is determined over the entire period of the experiment. In contrast, in the case of differential gene expression, the degree of expression of particular genes is detected at the respective time.
  • HGF is secreted by the dermal papilla, the control center of the hair follicle, to control cell proliferation in the hair matrix. Increased proliferation can thicken the hair matrix and potentially affect the volume of the hair fiber.
  • Physiological effects of treatment with potential agents for hair thickening can be determined by increasing the Outer Root Sheath Keratinocyte layer thickness in the hair follicle model by histologically analyzing three hair follicle models after 72 hours of incubation with drug or reference medium: fixation in 4 % Paraformaldehyde, staining with propidium iodide and microscopic analysis
  • fixation in 4 % Paraformaldehyde staining with propidium iodide and microscopic analysis
  • the thickness of the ORS keratinocyte layer of the hair follicle model is randomly measured and the results are presented in relation to the untreated control.
  • Table 5 Increase in the layer thickness after treatment of the hair follicle model with dandelion extract (0.1%) compared to the untreated control

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Birds (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation d'un produit contenant des principes actifs issus de plantes du genre pissenlit (Leontodon ou Taraxacum) pour traiter les cheveux, notamment pour revitaliser les cheveux, stimuler le métabolisme énergétique dans les follicules pileux, activer les follicules pileux, favoriser ou renforcer la pousse des cheveux, épaissir les cheveux, traiter la chute des cheveux et améliorer l'aspect des cheveux.
PCT/EP2007/059815 2006-10-06 2007-09-18 Utilisation d'extrait de pissenlit pour épaissir les cheveux et stimuler la pousse des cheveux Ceased WO2008043644A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006047733A DE102006047733A1 (de) 2006-10-06 2006-10-06 Verwendung von Löwenzahnextrakt zur Förderung der Haardicke und zur Stimulierung des Haarwuchses
DE102006047733.2 2006-10-06

Publications (2)

Publication Number Publication Date
WO2008043644A2 true WO2008043644A2 (fr) 2008-04-17
WO2008043644A3 WO2008043644A3 (fr) 2008-06-05

Family

ID=39106226

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/059815 Ceased WO2008043644A2 (fr) 2006-10-06 2007-09-18 Utilisation d'extrait de pissenlit pour épaissir les cheveux et stimuler la pousse des cheveux

Country Status (2)

Country Link
DE (1) DE102006047733A1 (fr)
WO (1) WO2008043644A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102549156A (zh) * 2009-10-05 2012-07-04 花王株式会社 毛发形状易感性基因
CN102549157A (zh) * 2009-10-05 2012-07-04 花王株式会社 毛发形状易感性基因
CN102575246A (zh) * 2009-10-05 2012-07-11 花王株式会社 毛发形状易感性基因
CN107616947A (zh) * 2017-08-29 2018-01-23 拉芳家化股份有限公司 一种具有头皮护理作用的护发素
CN113476492A (zh) * 2021-08-23 2021-10-08 盛春华 一种蒲公英籽浸膏及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3003166B1 (fr) * 2013-03-12 2015-04-10 Limousine D Applic Biolog Soc Ind Utilisation de fructanes de taraxacum officinale pour lutter contre les effets de la pollution de la peau

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US364408A (en) * 1887-06-07 James w
US375860A (en) * 1888-01-03 Hair-tonic
DE2255341A1 (de) * 1972-11-11 1974-05-30 Hubert Liehr Haarwasser
DE4118098C1 (fr) * 1991-06-03 1992-05-27 Externa-Junika Kosmetikvertriebsgesellschaft Mbh, 7000 Stuttgart, De
DE4331252A1 (de) * 1993-09-15 1994-05-19 Sylvia Warschkow Haargetränk und Haargel zur Haarbehandlung auf kosmetischer Basis bei Haarausfall und Haarneubewuchs
JP2000044439A (ja) * 1998-07-31 2000-02-15 Shiseido Co Ltd 頭皮頭髪用組成物
JP4033981B2 (ja) * 1998-09-24 2008-01-16 ツムラ ライフサイエンス株式会社 テストステロン ５α−リダクターゼ阻害剤
DE19927229B4 (de) * 1999-06-10 2004-09-09 Coty B.V. Enzymhaltiges Kosmetikum und dessen Verwendung
EP1074245A3 (fr) * 1999-08-06 2001-05-30 Sam Schwartz Composition avec des sels minéraux pour un traitement thérapeutique
HU227318B1 (en) * 2000-03-08 2011-03-28 Tibor Bodnar Cosmetical and dematological composition for treating, grooming of psoric skin and scalp
JP4627107B2 (ja) * 2000-07-06 2011-02-09 ライオン株式会社 毛髪外用剤組成物
JP2003221315A (ja) * 2002-01-25 2003-08-05 Kunio Tsuji 育毛用の皮膚外用剤
FR2865132A1 (fr) * 2004-07-06 2005-07-22 Oreal Utilisation de la diosmetine, d'un de ses derives ou d'un extrait de plante contenant l'un d'eux pour favoriser la pigmentation de la peau et/ou des cheveux

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102549156A (zh) * 2009-10-05 2012-07-04 花王株式会社 毛发形状易感性基因
CN102549157A (zh) * 2009-10-05 2012-07-04 花王株式会社 毛发形状易感性基因
CN102575246A (zh) * 2009-10-05 2012-07-11 花王株式会社 毛发形状易感性基因
CN102549157B (zh) * 2009-10-05 2015-07-01 花王株式会社 毛发形状易感性基因
CN102575246B (zh) * 2009-10-05 2015-07-01 花王株式会社 毛发形状易感性基因
CN102549156B (zh) * 2009-10-05 2015-07-01 花王株式会社 毛发形状易感性基因
US9243285B2 (en) 2009-10-05 2016-01-26 Kao Corporation Hair shape susceptibility gene
US9255264B2 (en) 2009-10-05 2016-02-09 Kao Corporation Hair shape susceptibility gene
US9255294B2 (en) 2009-10-05 2016-02-09 Kao Corporation Hair shape susceptibility gene
CN107616947A (zh) * 2017-08-29 2018-01-23 拉芳家化股份有限公司 一种具有头皮护理作用的护发素
CN113476492A (zh) * 2021-08-23 2021-10-08 盛春华 一种蒲公英籽浸膏及其应用

Also Published As

Publication number Publication date
DE102006047733A1 (de) 2008-04-10
WO2008043644A3 (fr) 2008-06-05

Similar Documents

Publication Publication Date Title
EP1899012B1 (fr) Agents contenant de la l-carnitine, des derives de l-carnitine et au moins une autre substance
DE102015222976A1 (de) Haarpflegemittel enthaltend Caseinhydrolysat zur Verbesserung der Haarstruktur
EP1812117A1 (fr) Procede de restructuration de fibres keratiniques
EP2020227B1 (fr) Dérivés de cellulose cationiques en cosmétique
EP1404286B1 (fr) Agent de soin capillaire comprenant un tartrate de carnitine
EP1927378A1 (fr) Agent de traitement capillaire comprenant de la quercetine et son utilisation pour revitaliser les cheveux
WO2008043644A2 (fr) Utilisation d'extrait de pissenlit pour épaissir les cheveux et stimuler la pousse des cheveux
EP2248509A2 (fr) Champoings doux pour les cheveux et le cuir chevelu et conditionneur
DE19823552A1 (de) Zubereitung zur Behandlung der menschlichen Haut und der menschlichen Haare mit einer speziellen Wirkstoffkombination sowie Verwendung dieser Wirkstoffkombination
EP1747045A1 (fr) Procede et composition pour restructurer des fibres de keratine
EP1779845B1 (fr) Utilisation de dérivés de cellulose cationiques en cosmétique
DE102011089366A1 (de) Haarwuchsmittel enthaltend Moringa Extrakt
EP2061426A1 (fr) Extrait de racine issu de harpagophytum pour stimuler la pousse des cheveux
DE102004045253A1 (de) Kationische Copolymere und ihre Verwendung in haarkosmetischen Zubereitungen
WO2006021350A1 (fr) Nouvel agent de traitement de fibres keratiniques
EP2061425A1 (fr) Extrait de apium graveolens pour stimuler la pousse des cheveux
DE102007013143A1 (de) Verwendung von Purin und Purinderivate zur Haarbehandlung
DE102013210463A1 (de) Haarwuchsmittel enthaltend Leontopodium Extrakt
DE10258394A1 (de) Tücher zur Pflege keratinischer Fasern
EP2054013A1 (fr) Bioquinones pour la stimulation de la synthèse kératinique
EP2097061A2 (fr) Utilisation de styphnolobium
WO2024193888A1 (fr) Dérivés de catéchol pour le traitement de signes de vieillissement des cheveux et/ou de vieillissement du cuir chevelu
DE102009028085A1 (de) Verwendung von Olivenöl und Proteinhydrolysaten in der Haarpflege
DE102013210466A1 (de) Haarbehandlungsmittel mit Lindera Extrakt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07820280

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07820280

Country of ref document: EP

Kind code of ref document: A2